Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

CMAB, a Suzhou Biologic CRO/CMO, Completes $38 Million A Round

publication date: Jan 2, 2018

CMAB Biopharma completed a $38 million Series A funding for its biologic CRO/CMO operations in Suzhou BioBay Park. The company offers process development and manufacturing services for biologic products. The funding was led by C-Bridge Capital, a healthcare PE investor involved mainly with China life science companies, along with BioBAY, a healthcare park, and joined by I-Bridge Capital and Qianhai FoF fund. I-Bridge is the early stage investor of the C-Bridge Group. CMAB intends to serve China and global biotech clients. More details...

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital